MVASI
NDC 55513-207 · Amgen, Inc
Generic namebevacizumab-awwb
Dosage formINJECTION, SOLUTION
RouteINTRAVENOUS
Active ingredient(s)BEVACIZUMAB
Strength400 mg/16mL
Pharmacologic classVascular Endothelial Growth Factor Inhibitor [EPC], Vascular Endothelial Growth Factor Inhibitors [MoA], Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]
Marketing categoryBLA
Packages
55513-207-01 — 1 VIAL in 1 CARTON (55513-207-01) / 16 mL in 1 VIAL
55513-207-21 — 1 VIAL in 1 CARTON (55513-207-21) / 16 mL in 1 VIAL
Billed under HCPCS
Q5107 — Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg Medicare Part B payment limit (ASP + 6%): $24.53
Related Codes
Same active ingredient
FDA lists these products with the same active ingredient.
0069-0315 — bevacizumab-bvzr, 0069-0342 — bevacizumab-bvzr, 50242-060 — bevacizumab, 50242-061 — bevacizumab, 55513-206 — bevacizumab-awwb, 70121-1754 — bevacizumab-maly, 70121-1755 — bevacizumab-maly, 72606-011 — bevacizumab-adcd, 72606-012 — bevacizumab-adcd, 82491-025 — bevacizumab-vikg, 83257-009 — bevacizumab-nwgd, 83257-010 — bevacizumab-nwgd